CEPI to fund Gennova's self­ amplifying mRNA vaccine against Disease X
Pune-based Gennova Biopharmaceuticals announced that its mRNA Covid-19 booster vaccine – Gemcovac - OM against the Omicron variant of SARS-CoV-2 received Emergency Use Authorization (EUA) from the office of the Drugs Controller General of India (DCGI).
The Drug Controller General of India (DCGI) has granted emergency use authorisation (EUA) for Gennova Biopharmaceuticals’ Omicron-specific mRNA-based Covid-19 booster vaccine, GEMCOVAC-OM.
Mumbai: Gennova Biopharmaceuticals, subsidiary of Pune-based drug maker Emcure on Tuesday said its mRNA Covid-19 booster vaccine - Gemcovac-OM against the Omicron variant of SARS-CoV-2 received emergency use authorization (EUA) from the Drugs Controller General of India (DCGI). nnnRead more at: nhttps://economictimes.indiatimes.com/industry/healthcare/biotech/pharmaceuticals/gennovas-mrna-booster-against-omicron-variant-gets-dcgi-nod/articleshow/101144122.cms?utm_source=contentofinterest&utm_medium=text&utm_campaign=cppst
Gennova Biopharmaceuticals, subsidiary of Pune-based drugmaker Emcure has submitted data for its mRNA-based Omicron specific Covid-19 booster shot for authorisation to the drug regulator, amid increase in the number of Covid-19 cases, a person i the know told ET.
NTAGI to discuss data of Gennova pharmaceuticals' indigenous mRNA vaccine
The Drugs Controller General of India (DCGI) on Tuesday approved India's first indigenously developed mRNA vaccine against COVID-19 manufactured by Gennova Biopharmaceuticals for restricted emergency use for those aged 18 years and above, official sources said on Tuesday.
New Delhi: The Subject Expert Committee (SEC) in a meeting held on Friday recommended Emergency Use Authorisation (EUA) for India's first mRNA COVID-19 vaccine, sources told on Tuesday.
MANASSAS, Va.--(BUSINESS WIRE)--ATCC, the world’s premier biological materials management, and standards organization, today announced that it has been awarded two contracts from Gennova Biopharmaceuticals Limited, on behalf of the U.S. Food and Drug Administration (FDA), to continue its work with the biotechnology company on a diagnostic test and vaccine for Leishmaniasis, a vector-borne, global protozoan endemic disease. ATCC will use its recognized expertise in providing critical gold standard reagents to develop Master Cell Banks (MCBs) and Working Cell Banks (WCBs) for the production of a Leishmania donovani diagnostic test and an attenuated Leishmania major vaccine.
India's first mRNA-based Covid-19 vaccine is one step closer to getting approval. Subject expert committee (SEC) of the country's drug regulator will soon review Pune-based Gennova Biopharmaceuticals' application seeking emergency use authorisation (EUA) for its vaccine, a person in the know told ET.